Wacker Biotech, a subsidiary of Wacker Chemie, today announced plans to acquire a production site for bioengineered pharmaceutical proteins (biologics), including the associated business, from BioNet Ventures. The two companies today signed the purchase agreement, which covers Wacker's acquisition of Scil Proteins Production, including the patent portfolio, at the Scil site at Halle, Germany. The transaction is expected to close early next year. Wacker will continue with existing customer partnerships, which Scil Proteins Production already has, and will retain...
Access is for Chemweek 24/7 PLUS Members ONLY
This information is only available to Chemweek 24/7 PLUS members who have subscribed to Chemweek’s Business Daily. If you are a member, please log in, OR if you have a trial membership, please use your trial membership account information.
Forgot your user ID or password? Click here to have it sent to you.